>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息：
重组人5型腺病毒H101联合索拉非尼对肝癌细胞株HepG2的体外抑制作用
作者：李璐璐1  张秀1  金萧萧1  王彩莲2  陈蓉2 
单位：1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 肿瘤科, 江苏 南京 210009
关键词：肝细胞癌 重组人5型腺病毒H101 索拉非尼 协同作用 
分类号：R735.7
出版年·卷·期（页码）：2016·35·第五期（673-677）
摘要：

目的：探讨重组人5型腺病毒H101联合索拉非尼（sorafenib）体外对人肝癌细胞株HepG2增殖及凋亡的影响。方法：将重组人5型腺病毒H101和索拉非尼分成单用组及联合用药组，作用于HepG2细胞，另设不加药对照组。CCK-8法检测HepG2细胞存活率，流式细胞术及DAPI染色检测HepG2细胞凋亡。结果：重组人5型腺病毒H101及索拉非尼均可显著抑制HepG2细胞增殖并诱导其凋亡；与重组人5型腺病毒H101或索拉非尼单用相比，两药联合对HepG2细胞增殖抑制及诱导凋亡作用更为显著（均P<0.05）。结论：重组人5型腺病毒H101、索拉非尼单用及联用均能体外抑制HepG2细胞增殖并诱导其凋亡，且在特定索拉非尼浓度范围内两药联合存在协同作用。

Objective:To investigate the inhibitory effect of recombinant adenovirus H101 combined with sorafenib on the proliferation and apoptosis of hepatocellular cell line HepG2 in vitro. Methods:HepG2 cells were treated with H101, sorafenib alone and in combination with the untreated cells used as control. The proliferation inhibition effect was determined using CCK-8 assay. Apoptosis was analyzed by flow cytometry and 4,6-Diamidino-2-phenylindole (DAPI) staining. Results:Oncolytic adenovirus H101 and sorafenib used alone or together both inhibited the proliferation of HepG2 cells and induced cell apoptosis. Compared with H101 or sorafenib alone, co-treatment led to a stronger antitumor effect in HepG2 cells. Conclusion:Oncolytic adenovirus H101 and sorafenib show a synergistic effect in inhibiting the proliferation and inducing apoptosis of HepG2 cells.
参考文献：

[1] DING J,WANG H.Multiple interactive factors in hepatocarcinogenesis[J].Cancer Letters,2014,346(1):17-23.
[2] CHENG A L,KANG Y K,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomized,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
[3] LLOVE J M,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
[4] YU W,FANG H.Clinical trials with oncolytic adenovirus in China[J].Curr Cancer Drug Targets,2007,7(2):141-148.
[5] 赵健,吕岩,郭亚军.E1B55kDa缺陷型腺病毒对人肝癌细胞的杀伤研究[J].中华肿瘤杂志,2001,23(5):366-368.
[6] CRISSIEN A M,FRENETTE C.Current management of hepatocellular carcinoma[J].Gastroenterol Hepatol (N Y),2014,10(3):153-161.
[7] RUSSELL S J,PENG K W,BELL J C.Oncolytic virotherapy[J].Nat Biotechnol,2012,30(7):658-670.
[8] RUSSELL S J,PENG K W.Viruses as anticancer drugs[J].Trends Pharmacol Sci,2007,28(7):326-333.
[9] UUSI-KERTTULA H,HULIN-CURTIS S,DAVIES J,et al.Oncolytic adenovirus:strategies and insights for vector design and immuno-oncolytic applications[J].Viruses,2015,7(11):6009-6042.
[10] LOUSTALOT F,KREMER E J,SALINAS S.Membrane dynamics and signaling of the coxsackievirus and adenovirus receptor[J].Int Rev Cell Mol Biol,2016,322:331-362.
[11] LIN X J,LI Q J,LAO X M,et al.Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)[J].BMC Cancer,2015,15:707.
[12] CUN B,SONG X,JIA R,et al.Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle block[J].Cancer Biol Ther,2012,13(2):77-84.
[13] SONG X,ZHOU Y,JIA R,et al.Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101[J].Invest Ophthalmol Vis Sci,2010,51(5):2626-2635.
[14] LIU R Y,ZHOU L,ZHANG Y L,et al.An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells[J].Biochem Biophys Res Commun,2013,442(3-4):171-176.
[15] LU W,ZHENG S,LI X F,et al.Intra-tumor injection of H101,a recombinant adenovirus,in combination with chemotherapy in patients with advanced cancers:a pilot phase II clinical trial[J].World J Gastroenterol,2004,10(24):3634-3638.
[16] HEO J,BREITBACH C J,MOON A,et al.Sequential therapy with JX-594,a targeted oncolytic poxvirus,followed by sorafenib in hepatocellular carcinoma:preclinical and clinical demonstration of combination efficacy[J].Mol Ther,2011,19(6):1170-1179.
[17] KHURI F R,NEMUNAITIS J,GANLY I,et al.A controlled trial of intratumoral ONYX-015,a selectively-replicating adenovirus,in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J].Nat Med,2000,6(8):879-885.
服务与反馈：
【文章下载】【发表评论】【查看评论】【加入收藏】
提示：您还未登录，请登录！点此登录
您是第 415170 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话：025-83272481 83272483
电子邮件： bjb@pub.seu.edu.cn

苏ICP备09058364